PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/672,724
Filing Date	9/25/2003
First Named Inventor	Robinson et al.
Art Unit	1617
Examiner Name	Wang
Attorney Docket Number	UCI-12094

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CH	1	US- 5,705,647	01/06/1998	Babu et al.	whole document
CH	2	US- 4,724,232	02/09/1988	Rideout et al.	whole document
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
CH	3	WO 00/63152	10/26/2000	Burke et al.	whole documetn	

Examiner Signature	Carlie Hwynh	Date Considered	4/18/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	10/672,724
Filing Date	9/25/2003
First Named Inventor	Robinson et al.
Art Unit	1617
Examiner Name	Wang
Attorney Docket Number	UCI-12094

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
CH	4	Robinson et al., "Inhibitors of HIV-1 replication that inhibit HIV integrase," PNAS 93:6326-6331 (1996)	
CH	5	Deeks et al., "HIV-1 Protease Inhibitors," JAMA 277:145-153 (1997)	
CH	6	Konig et al., "The Caffeoylics as a New Family of Natural Antiviral Compounds," Naturwissenschaften 72:659-661 (1985)	
CH	7	King et al., "Resistance to the Anti-Human Immunodeficiency Virus Type 1 Compounds L-Chicoric Acid Results from a Single Mutation at Amino Acid 140 of Integrase," J. of Virology 72:8420-8424 (1998)	
CH	8	King et al., "Structure-Activity Relationships: Analogues of the Dicaffeoylquinic and Dicaffeoyltartaric Acids as Potent Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and Replication, J. Med. Chem. 42:497-509 (1999)	
CH	9	Starnes et al., "Cellular Metabolism of 2',3'-Dideoxycytidine, a Compounds Active against Human Immunodeficiency Virus in Vitro," J. Biol Chem. 262:988-991 (1987)	
CH	10	Robinson, Jr., "L-Chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitor anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350)," Antiviral Res. 39:101-111 (1998)	
CH	11	McDougall et al., "Dicaffeoylquinic and Dicaffeoyltartaric Acids Are Selective Inhibitors of Human Immunodeficiency Virus Type 1 Integrase," Antimicrobial Agents and Chemotherapy 42:140-146 (1998)	
CH	12	Beale et al., "Combinations of reverse transcriptase, protease, and integrase inhibitors can be synergistic in vitro against drug-sensitive and RT inhibitor-resistant molecular clones of HIV-1," Antiviral Res. 45:223-232 (2000)	
CH	13	Farnet et al., "Human Immunodeficiency Virus Type 1 cDNA Integration: New Aromatic Hydroxylated Inhibitors and Studies of the Inhibition Mechanism," Antimicrobial Agents and Chemotherapy 42:224502253 (1998)	

Examiner Signature	Carlos Azpuru	Date Considered	4/18/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.